A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to
evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute
treatment of migraine.